The safety of beclomethasone dipropionate in the treatment of ulcerative colitis.

Article Details

Citation
Copy to clipboard

Rizzello F, Mazza M, Salice M, Calabrese C, Calafiore A, Campieri M, Gionchetti P

The safety of beclomethasone dipropionate in the treatment of ulcerative colitis.

Expert Opin Drug Saf. 2018 Sep;17(9):963-969. doi: 10.1080/14740338.2018.1510914. Epub 2018 Aug 21.

PubMed ID
30101623 [ View in PubMed
]
Abstract

INTRODUCTION: Beclomethasone dipropionate (BDP) is a second-generation corticosteroid that uses novel drug technologies to ensure colonic targeting and potentially reducing systemic corticosteroid concentrations. It is approved for treatment of patients with mild-to-moderate ulcerative colitis (UC) who do not respond to mesalazine. The gut-selective mechanism of action has the potential to improve the safety profile of BDP compared with other conventional corticosteroids. Areas covered: We reviewed the mechanism of action, efficacy, and safety of BDP in the treatment of UC. The positioning of BDP in management algorithms is also discussed. Expert opinion: The highly selective mechanism of action of BDP restricts the steroid-related side effects. BDP is efficacious in the treatment of active UC. Topical formulation is the first choice in distal UC, while oral formulation is used in patients with an extensive involvement of the colon. The rates of adverse events (AE), serious AEs, and steroid-related side-effects are similar to placebo and mesalamine and slightly inferior to traditional corticosteroids.

DrugBank Data that Cites this Article

Drugs